The patent covering the tablet formulation of Oncoral has now been approved by the US Patent and Trademark Office. The patent covers a period of 20 years to year 2034 with potential extension to year 2039.
“We are very pleased with the approval of the patent application, which significantly increases the value of Oncoral. This approval marks yet another important milestone in the development of Oncoral and we are dedicated to make this novel anti-cancer tablet available to patients”, says Magnus Corfitzen, Chief Executive Officer of Ascelia Pharma.
The patent covers the unique and proprietary tablet formulation of Irinotecan for treatment of cancer. The Oncoral tablet formulation is currently in a Phase I study at Herlev Hospital in greater Copenhagen. The study is approaching completion and data from the study is expected to be presented later this year. The first part of the Phase I study investigates the safety and tolerability when Oncoral is given as a single chemotherapeutic agent, while the second part of the study investigates the combination of Oncoral together with another oral chemotherapeutic drug (an all-oral chemotherapy combination).
For further information contact:
Magnus Corfitzen, CEO, +46 735 179 110
About Ascelia Pharma
Ascelia Pharma is a specialty pharmaceutical company dedicated to the development of novel medicines to improve the life expectancy and quality of life for people living with cancer. The company is located at Medeon in Malmö, Sweden in the middle of Medicon Valley, a leading European life science cluster. For more information, please visit www.ascelia.com